Bioventus (BVS)
(Delayed Data from NSDQ)
$3.99 USD
+0.03 (0.76%)
Updated May 1, 2024 04:00 PM ET
After-Market: $3.99 0.00 (0.00%) 7:22 PM ET
4-Sell of 5 4
B Value A Growth B Momentum A VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BVS 3.99 +0.03(0.76%)
Will BVS be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BVS
PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates
Bioventus (BVS) to Report Q3 Earnings: What's in the Cards?
BVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
3 Value Medical Stocks to Buy for Safety Amid Market Volatility
Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates
AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1
Other News for BVS
Bioventus to Report First Quarter of Fiscal Year 2024 Financial Results on May 7, 2024
Notable Two Hundred Day Moving Average Cross - BVS
Atrion Corporation Is Overvalued For The Direction Fundamentals Are Heading
Blend Labs Reports Q4 Results, Joins Alta Equipment, Despegar.com And Other Big Stocks Moving Higher On Friday
Bioventus price target raised by $3 at Craig-Hallum, here's why